Teva Wins Bidding For NuPathe And Its Migraine Patch, Topping Endo
This article was originally published in The Pink Sheet Daily
Teva will be responsible for launching the Zecuity migraine patch after acquiring NuPathe for $144 million upfront. Teva’s $3.65 per share offer for NuPathe trumps Endo’s $2.85 per share, or $105 million, offer.
You may also be interested in...
FDA worries about burning and scarring with the battery-powered Zecuity patch prompted NuPathe to reconfigure the drug-device combo; our Drug Review Profile shows how FDA thought the problem was solved, but adverse reaction reports soon after launch led to marketing suspension.
NuPathe and its migraine patch product Zecuity are the latest acquisition by Endo since former Valeant executive Rajiv De Silva moved into the chief executive’s office – will he succeed in bringing his former company’s model to the specialty firm? Plus, Valeant made its own news during the week, while AstraZeneca bought out Bristol’s share of their diabetes joint venture, and more.
Allergan/MAP Planned Merger, Approval Of NuPathe’s Triptan Patch Change U.S. Landscape For Migraine Therapy
While Allergan plans to diversify its portfolio in migraine by acquiring partner MAP and its candidate for acute migraine, NuPathe seeks a partner for a triptan patch product expected to avoid the nausea suffered by many migraine patients.